Previous 10 | Next 10 |
Thinly traded micro cap BeyondSpring (NASDAQ: BYSI ) is down 21% premarket on increased volume, albeit on turnover of only 22K shares, in reaction its public offering of ~1.9M ordinary shares at $13.50 per share. More news on: BeyondSpring Inc., Healthcare stocks news, Stocks...
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, toda...
BeyondSpring (NASDAQ: BYSI ) tanks 19.2% in pre-market after the company announced a public offering led by Decheng Capital. More news on: BeyondSpring Inc., Healthcare stocks news, Read more ...
The first patient has been enrolled in a Phase 3 clinical trial, Study 106, evaluating BeyondSpring's ( BYSI -4.1% ) lead candidate Plinabulin for the prevention of chemotherapy-induced neutropenia (CIN) (abnormally low levels of a type of immune cell call neutrophils). ...
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical t...
NEW YORK, Oct. 17, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 10,357,4...
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that Cell Press publications Chem and Cell Reports , two peer-reviewed s...
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today announced that the Company’s novel trial design for DUBLIN-3 (Study BPI-2358-103) for ...
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that a Company abstract with findings from BeyondSpring’s Study 106 has been accepted for p...
Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI) Q2 2019 Earnings Call Sep 18, 2019 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...